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ABSTRACT
SOROKA, STANLEY Point Mutations of the Putative Follitropin Receptor
Caveolin Interaction Motif Do Not Disrupt Receptor Function.
Biochemistry Department, June 2016
ADVISOR: Brian D. Cohen
Human follicle stimulating hormone (hFSH) is a hormone found in humans that is
synthesized and secreted by the anterior pituitary and targets the ovaries and testes. This
specificity of targeting is accomplished by the interaction of hFSH with its receptor
(hFSHR) on target cells. hFSHR is a G protein-coupled receptor that localizes to domains
in the cell membrane known as lipid rafts. The mechanism of translocation of the hFSHR
into lipid rafts is unknown.

Our hypothesis is that translocation occurs through

interaction of hFSHR with the protein caveolin via a specific sequence in the hFSHR; a
putative caveolin interaction motif (CIM). The canonical caveolin interaction motif,
FXFXXXXFXXF, where F is any aromatic amino acid such as phenylalanine (F),
tyrosine (Y) or tryptophan (W) is found in the fourth transmembrane domain of hFSHR
in amino acids 479-489 (FAFAAALFPIF). Here, the 4 critical phenylalanine residues
match the motif. The goal of the current research has been to produce stable cell lines
expressing isoforms of hFSHR with one of each of the four phenylalanines mutated to
leucine. The mutant receptors were expressed in the cells and qualitatively demonstrated
normal signaling when stimulated by hFSH. Future studies will focus on analyzing
quantitative measurement of signaling and the location of the mutant receptor on the cell
surface. Understanding the caveolin interaction motif of hFSHR could give us better
understanding of the mechanism of hFSHR localization to lipid rafts and may give
insight

into

a

novel

way

to

regulate

FSH

signaling

and

function.
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Introduction
Plasma Membrane
Every cell is constructed with a plasma membrane separating the interior of the
cell from its surroundings. As shown in Figure 1, this membrane is a combination of
lipids, proteins, and in the case of eukaryotes, sterols. 1 The most common lipids in the

Figure 1. Singer-Nicolson Augmented model of the plasma membrane.
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membrane are phosphatidylcholine, phosphatidylethanolamine, phosphatidylserine, and
sphingomyelin.

2

These

lipids

all

have

cylindrical Van der Waals envelopes (Figure
2);

when

the

lipids

are

in

aqueous

environments, the hydrophobic tails are pushed
together forming a bilayer. This is known as
the hydrophobic effect. 3 Because the middle of

Figure 2. Cylindrical, bilayer lipid and the bilayer it
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forms in aqueous solutions. .

the plasma membrane is hydrophobic, the cell is impermeable to water-soluble
molecules.

1

Although not all of the lipids have hydrocarbon tails with double bonds, when
double bonds are present, they are usually cis, introducing kinks into the tails.

2

This

makes them difficult to pack together and for this reason, the tails move freely within the
membrane; there is also uncatalyzed lateral diffusion of the lipids themselves. 2 In animal
cells, cholesterol is present in the membrane to increase or decrease fluidity, as
necessary; it inserts itself into the bilayer, between lipids, with its polar hydroxyl group. 2
The presence of cholesterol in between the lipids keeps the fatty acid tails from coming
together and freezing at low temperatures. At high temperatures, cholesterol does the
opposite. Its presence in between lipids interferes with the rotation of the fatty acid tails,
limiting their movement.

2

G-Protein Coupled Receptors
Within the membrane are many
different families of receptors. One of the
largest superfamilies of membrane-bound
receptors is the g protein coupled receptors
(GPCRs). 4 GPCRs make up about 3% of all
human genes representing between 750 and
800 different GPCRs.

Individual cells

express less than 100 different GPCRs, a
number of different G protein subunits, and
various

G

protein-linked

effectors.

4

Transmission of a signal by GPCRs requires

Figure 3. The activation of adenylyl cyclase as a result
of ligand binding to a GPCR. Binding activates the
GPCR which then promotes the exchange of GDP for
GTP in the alpha subunit. The alpha unit can then
activate effector proteins, such as adenylyl cyclase.

physical interaction between the receptor, a guanosine nucleotide-binding protein (G
protein) subunit, and an effector molecule. 4 Signal transduction occurs when the receptor
2

is activated by its ligand. This interaction causes a conformational change in the receptor
that allows it to function as a guanine exchange factor (GEF). 5 As a GEF, the receptor
acts on its coupled, inactive G protein on the cytosolic side of the membrane.

It

facilitates the release of bound GDP from the G protein and binding of free GTP from the
cytosol, activating the G protein. Once activated, the G protein dissociates from the
receptor and binds to a nearby effector protein, usually an enzyme. This binding alters
the activity of the enzyme. 5
These components required for signaling, however, are expressed on the cell
surface at relatively low levels, less than 10,000/cell. 6 At these concentrations, a uniform
distribution of the components would be extremely unlikely to allow for interaction and
sufficient signal transduction, but somehow signal transduction still occurs rapidly and
efficiently. One mechanism that may explain how signal transduction is facilitated is that
cells concentrate signaling molecules within membrane microdomains.

4

Lipid Rafts
The multitude of saturated hydrocarbon chains in cell membrane sphingolipids
allows for cholesterol to be tightly intercalated. 7 This leads to membrane rigidity and the
formation of microdomains known as lipid rafts. 8 The tight packing of the cholesterol
and sphingolipids within the membrane causes the high melting temperature of these
microdomains. 9 Rafts can be characterized as caveolar or non-caveolar; caveolar lipid
rafts are flask shaped invaginations in the membrane and non-caveolar rafts are planar
microdomains. 10
Studies have concluded that lipid rafts provide both a spatial and temporal
meeting point for signaling molecules. It is believed that lipid rafts can coordinate
specific signaling events by influencing the inclusion or exclusion of receptors and their
3

associated effector molecules.

10

Lipid rafts also influence g protein-coupled-receptor

signaling (GPCR). 10 Lipid rafts can localize or move any of the components required for
transducing the signal as a way of modifying receptor signaling. Studies show, however,
that GPCR components are more likely to be confined within lipid rafts.

4

This may

explain how stable complexes are able to be formed between the separate components of
the GPCR pathway. Disrupting lipid rafts has resulted in reductions in G protein coupling
and binding of agonists to GPCRs, providing support to the theory that lipid rafts
facilitate coupling of the G protein and receptor. 4 Many of these couplings have been
found to occur in the previously mentioned lipid raft subsets called caveolae.

Figure 4. Linear and Caveolar Lipid Rafts
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Caveolae
Caveolae are thought to be a subset of lipid rafts that comprise about 1% of the
plasma membrane surface area of the cells that express them. They are approximately
50-100 nm in diameter and were first identified during the 1950s by their “flask-shape”
on the cell surface.

In addition to the usual characteristics of lipid rafts, caveolae

characteristically contain caveolin proteins localized on the inner leaflet of the membrane
bilayer. 11 Caveolae are present in cells from most tissues but are particularly abundant in
adipocytes, endothelial cells, type I pneumocytes, fibroblasts, and smooth and striated
muscle cells. Alternatively, cells such as neurons and lymphocytes normally lack
caveolae.

12

Within caveolin expressing cells, caveolae function in transcytosis,

endocytosis, exocytosis, cholesterol homeostasis, and receptor and ion-channel
expression, activation, and desensitization. 12

Figure 5. Schematic representation of the lipid and protein organization of caveolae
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Caveolin
Caveolin proteins are located solely on the cytoplasmic side of the plasma membrane
and are considered the molecular markers for caveolae. Three different isoforms of the
protein exist: caveolin-1, caveolin-2, and caveolin-3. Caveolae generally form in cells
expressing caveolin-1, the predominant isoform, or caveolin-3, the striated musclespecific isoform. 13 Caveolin-2 is found in hetero-oligomers with caveolin-1 and
caveolin-3, but it is not clear if caveolin-2 can induce caveolae biosynthesis on its own. 14
The three isoforms have a similar structure consisting of a hairpin loop with both the C
and N termini on the cytoplasmic side of the membrane. Knock out experiments
performed in mice show that the isoforms have different patterns of regulation of
enzymatic and functional activities. 12
Within caveolae, caveolin has three major functions. First, it helps maintain the
structural integrity of the caveolae. The curvature of the membrane creates physical stress
on the membrane that caveolin helps to alleviate by “filling in” the stretched side of the
membrane (Figure 4). 15 Secondly, caveolin acts as a scaffolding protein. In this role,
caveolin recruits various molecules into the raft region. Lastly, caveolin acts as a protein
chaperone and functions in cell membrane trafficking. 15
Multiple domains have been identified within the structure of the caveolin monomer.
The scaffolding domain that exists likely serves as an anchor for signaling components.
Caveolin also contains and oligomerization domain. This is the site of interaction where
the high-weight oligomers seen in the caveolae are formed. 15
Caveolin Interaction Motif
Previous research has suggested that signaling proteins form direct protein-protein
interactions with the scaffolding domain of caveolin (CSD) through a conserved peptide
6

sequence, the caveolin binding motif (CBM). 16 These consensus CBMs are hydrophobic
and rich in aromatic residues. The typical sequences are 𝜙x𝜙xxxx𝜙 or 𝜙xxxx𝜙xx𝜙 or
the combined sequence 𝜙x𝜙xxxx𝜙xx𝜙, where 𝜙 is a phenylalanine, tyrosine or
tryptophan residue and x can be any amino acid (figure 6). 16

Figure 6. Caveolin interaction motif and conjugate amino acid sequence on scaffolding domain of caveolin
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Human Follicle Stimulating Hormone Receptor
Follicle stimulating hormone, or follitropin, is a gonadotropin hormone secreted
by the gonadotroph cells in the anterior pituitary. 17 In order to transduce a signal, FSH
binds to its receptor, follicle stimulating hormone receptor (FSHR). FSHR is found on the
surface of granulosa cells surrounding the immature follicle and oocyte in ovaries of
women and on Sertoli cells in the testes of men. 17 Activation of FSHR by FSH directly
promotes follicle maturation and estrogen production in females. 18 In males, FSH plays a
role in establishing the population of Sertoli cells in the testicular seminiferous tubules
and in the maintenance of sperm quality and number. 17
These aforementioned effects are the result of FSHR signaling through what is
known as its canonical pathway. When FSH binds to FSHR, the receptor transduces a
signal through two different pathways, the canonical pathway and what is believed to be
a desensitization and internalization pathway.
7

FSHR is a GPCR (Figure 7). The canonical pathway is dependent on FSHR’s
action through it coupled G protein. FSHR is primarily coupled to the G protein GSα. 19

Figure 7. hFSHR and its signaling pathways

When activated, GSα alters the activity of the enzyme adenylyl cyclase, stimulating the
production of cyclic AMP (cAMP). cAMP then activates Protein kinase A (PKA), which
can activate the cAMP Response Element Binding Protein (CREB) pathway (Figure 3). 19
This results in the previously discussed endocrine effects of FSH.
Prolonged exposure to FSH, however, leads to desensitization. This is decreased
sensitivity and response to the hormone. 20 Desensitization is a result of receptor
uncoupling, which decreases receptor function and occurs relatively rapidly after receptor
stimulation. 20 FSHR is uncoupled from the GSα subunit due to phosphorylation of serine
and threonine residues on the C terminal end of the receptor. This event results in the
recruitment of inhibitor proteins known as arrestins. 21 Arrestins then recruit other
8

molecules that play a role in receptor down-regulation. 20 This is a slower desensitization
process. The number of FSHRs on the cell surface decrease due to internalization through
clathrin coated pit or caveolae endocytotic pathways. 22 Receptor numbers also begin to
decrease as a result of decreased transcription, translation, or mRNA half-life.
Human FSHR (hFSHR), like other GPCRs, has been shown to preferentially
localize within microdomains in the cell membrane known as lipid rafts during signaling.
23

More specifically, hFSHR has been observed to associate with caveolae (Cohen Lab).

Research has shown that lipid rafts function as spatial and temporal meeting places for
the molecules required to transduce a signal, like GPCRs. 24
FSHR And Lipid Rafts
The hFSHR sequence contains a canonical combined motif between amino acids
479-489 (Figure 8) with each of the 𝜙’s of the CBD being a phenylalanine.10 In Figure 8,
these residues are colored in with 479 as green and 489 as blue. This provides a possible
mechanism for the interaction of hFSHR with caveolin, although it does not help to
understand the functional significance of either the sequence or the interaction.

Caveolin Interaction Motif
Ф X Ф X X X X Ф X X Ф
F A F A A A L F P I F
479 481
486
489

Figure 8. hFSHR with combined caveolin interaction motif circled
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To study the interactions of hFSHR with caveolin, mutated receptors have been
synthesized. Members of the Cohen lab individually mutated each of the phenylalanine
residues of the CBD to a leucine residue using Splicing by Overlap Extension (Table 1).
9

Table 1. FSH receptor Mutagenesis Oligonucleotides for Splicing by Overlap Extension

FSH Receptor Mutagenesis Oligonucleotides
Normal

5’GTCATGGTGATGGGCTGGATTTTTGCTTTTGCAGCTGCCCTCTTTCCCATCTTTGGCATCAGCAGCTACATGAAG 3’

Sequence

3’CAGTACCACTACCCGACCTAAAAACGAAAACGTCGACGGGAGAAAGGGTAGAAACCGTAGTCGTCGATGTACTTC 5’

F479L

5’GGCTGGATCCTTGCTTTTGCAGCTGCCCTC3’ C primer
3’CAGTACCACTACCCGACCTAGGAACGAAAACG5’
B primer
GCAAAAGCAAGGATCCAGCCCATCACCATGAC

F481L

5’GATTTTTGCGCTAGCAGCTGCCCTCTTTCCC3’ C primer
3’CACTACCCGACCTAAAAACGCGATCGTCGACGG5’
B primer
GGCAGCTGCTAGCGCAAAAATCCAGCCCATCAC
EarI

F486L
AvrII

F489L

BamHI

NheI

5’GCAGCTGCTCTTCTTCCCATCTTTGGCATCAGC3’ C primer
3’CTAAAAACGAAAACGTCGACGAGAAGAAGGGTAG5’
B primer
GATGGGAAGAAGAGCAGCTGCAAAAGCAAAAATC
5’TTTCCCATCCTAGGCATCAGCAGCTACATGAAG3’C primer
3’CGACGGGAGAAAGGGTAGGATCCGTAGTCG5’
B primer
GCTGATGCCTAGGATGGGAAAGAGGGCAGC

The next step of this research is to transfect the mutated receptors into HEK293 cells.
These transfected cells will be examined for proper expression of the receptor. If the
receptors are expressed properly, they will be tested for co-immunoprecipitation with
caveolin and proper signal transduction.
Once the interaction between hFSHR and the lipid rafts is better understood,
research can be focused on possible pharmaceutical interventions for infertility and novel
birth control. Specifically, research will be focused on synthesis of two different drugs,
one that would enhance interaction between the receptor and caveolin and one that would
interfere with the interactions.

10

Methods
Cell Culture and DNA Transfection
HEK293 cells were grown and maintained as monolayer cultures at 37°C in DMEM
medium supplemented with 10% fetal bovine serum and penicillin:streptomycin. The
cells were grown to 50-70% confluence before being transfected using X-tremeGENE
HP DNA Transfection Reagent Roche) and the respective DNA. The HEK293 cells were
transfected with wild-type or mutant FSHR plasmids for expression, localization, and
signaling assays.

SDS-PAGE and Western Blotting
HEK293 cells were grown to a monolayer and transfected. The cell’s proteins were then
extracted by detergent lysis. An Igepal/DOC lysis buffer (1% Igepal, 0.4% deoxycholate,
10mM Tris-Cl pH 7, 6.6mM EDTA) was used with a 1X protease inhibitor cocktail.
After BCA Assay analysis, the protein samples were linearized by treatment with SDS
and separated on 10% poly-acrylamide gels by molecular mass. The proteins were then
transferred to a PVDF membrane and blocked with 5% milk in TBST. The membranes
were then probed with various antibodies. Anti-hFSHR mAb 106.105 (105) was used to
probe for hFSHR, P-p44/42 MAPK Rabbit Ab for phosphorylated p44, P-CREB Rabbit
Ab for phosphorylated CREB, and p38 MAPK Rabbit Ab for total p38. Finally, the
membranes were probed with anti-mouse HRP antibody when probing with 105 and with
anti-rabbit HRP when probing with phospho-p44, phospho-CREB, or p38.

11

Immunohistochemistry
HEK293 cells were grown on glass cover slips and then transfected with wild-type or
mutant FSHR plasmids. These cells were fixed using 4% paraformaldehyde in phosphate
buffered saline (PBS). Primary antibody for the detection of FSHR was monoclonal
antibody mAb106.105, the kind gift of Dr. James Dias (Wadsworth Center, Albany, NY).
Goat anti-mouse with an Alexa-Red fluorophore was used as the secondary antibody.

Stable Selection
HEK293 cells were grown and transfected as described in Cell Culture and DNA
Transfection. The medium was then changed to one including G418 antibiotic in order to
select for only the cells that were successfully transfected. After several days in the G418
medium, single colonies of the cells were transferred to their own wells of a 24-well dish
for their amplification. Once they reached confluence, they were moved to 12-well
dishes, 6-well dishes, t-25 flasks, and finally t-75 flasks.

12

Results
Single point mutations of the caveolin interaction motif do not disrupt receptor
expression.
SDS-PAGE and western blotting assays were performed to determine whether
mutations of single aromatic residues of the caveolin interaction motif disrupted the
expression of the mutant receptors by cells. Results show that all four of the mutant
receptors, and the wild type receptor, were successfully transfected into HEK293 cells

F4
89
L

F4
86
L

F4
81
L

F4
79
L

W
Th
FS

M

W

HR

and the cells were able to express them (Figure 9).

Figure 9. Western blot of lysates transfected with wild-type and mutant hFSHR plasmids. Probed with
anti-hFSHR mAb 106.105 for the detection of FSHR.

Expression of the mutant receptors was also analyzed by fluorescence
microscopy. Results support that the cells were successfully transfected with the wild
type and mutant receptors and the cells express each of the receptors (Figure 10).

13

HEK 293

F479L

F486L

Wild Type

F481L

F489L

Figure 10. Fluorescence imaging of HEK293 cells transfected with nothing, wild type hFSHR, and the three hFSHR single mutant
plasmids. Cells were stained with Alexa 594 Goat anti-Mouse Ab and DAPI.
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Single point mutations of the caveolin interaction motif do not disrupt receptor signaling
SDS-PAGE and western blotting assays were performed to determine whether
mutations of single aromatic residues of the caveolin interaction motif disrupted the
ability of the mutant receptors to signal through the CREB and MAPK pathways when
exposed to hormone for 0, 5, and 15 minutes before protein extraction. Results show that
all four of the mutant receptors, and the wild type receptor, successfully signaled through
both pathways in response to hormone stimulation (Figures 11 and 12).

WT

p38
479 481 486 489

pCREB
WT

479

481 486 489

0 min FSH

5 min FSH

15 min FSH
Figure 12. Western blot analysis of protein lysates from HEK293 cells transfected with wild type and single mutant
hFSHR plasmids probed with p38 MAPK Rabbit Ab as a loading control and P-CREB Rabbit Ab to determine signaling by
the canonical pathway.

10
WT 4795481 486 489

Total p38
WT 479 481 486 489

pp44
WT 479 481 486 489

0 min FSH

5 min FSH

Western blot analysis of protein lysates from HEK293 cells transfected with wild type and single mutant
15Figure
min11.FSH

hFSHR plasmids probed with anti-hFSHR mAb 106.105 to show hFSH expression, p38 MAPK Rabbit Ab as a loading
control and P-p44/42 MAPK Rabbit Ab to determine signaling by the internalization pathway.
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Discussion
Four variant hFSHR plasmids with mutations in the caveolin interaction motif
were previously created using splicing by overlap extension. The phenylalanine residues
of the caveolin interaction motif were mutated to leucine residues at amino acids 479,
481, 486, and 489 of the hFSHR. These plasmids were transfected into human
embryonic kidney (HEK293) cells for various assays to determine the effect of the
mutations on properties of the receptor.
Western blot analysis using anti-hFSHR mAb 106.105, an hFSHR-detecting
antibody, demonstrated that the wild type and mutant receptors were present in the
transfected cells. Therefore, the single residue mutations did not affect the ability of the
cells to transcribe and translate the plasmids into receptor proteins.
In order to determine if the mutant receptors could also be localized to the cell
membrane by HEK293 cells, fluorescence microscopy assays using fluorescently tagged
mAb 106.105 were performed. Results show that the wild type and mutants receptors
were indeed localized to the cell membrane in the HEK293 cells. The transfected cells
were not permeablized prior to incubation with mAb 106.105 and the fluorescently
tagged secondary antibody so any fluorescence seen should correspond to antibody
bound to receptors on the cell surface.
Receptor localization to the cell surface was also confirmed by western blot
analysis using anti-Phospho p44 and anti-Phospho-CREB. These antibodies detect
phosphorylated p44 and CREB molecules. p44 and CREB are phosphorylated
downstream of two FSHR signaling pathways. Levels of phosphorylated p44 and CREB
were measured at 0, 5, and 15 minutes of exposure to FSH in order to determine if the

16

mutant receptors signaled like the wild type receptor. Results show that the wild type and
mutant receptors each signal in response to hormone stimulation. Variability in gel
loading was observed (based on the total p38 staining in Figures 11 and 12) which
prevents quantitative analysis of signaling activation by the mutant receptors. However,
any signaling is demonstrative of the presence of hFSHR CIM mutants on the cell
membrane.
Taken together, these results indicate that single mutations of a phenylalanine
residue of the caveolin interaction motif do not disrupt completely disrupt expression,
localization, and signaling of the hFSHR. The qualitative assays performed did not rule
out the possibility that the mutations impacted the level of expression, localization to the
cell surface, or signaling efficiency of the hFSHR mutants as compared to the wild type.
Future experiments should include selection of stable cell lines expressing the
mutant hFSHRs. With stably selected cell lines, the quantitative expression assays can be
performed and once expression is determined for the different mutants, the surface
localization and signaling can be normalized to the number of receptors. This will allow
the researchers to compare the mutant and wild type receptors quantitatively on a perreceptor basis and the effect of the mutations on receptor properties will be better
understood.
Once the effect of the single mutations is better understood, the focus can be
turned to creating multiple mutants and performing different assays to see if additional
mutations of the phenylalanine residues of the caveolin interaction motif will result in
disruption of proper hFSHR function.
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not affect product performance or product stability.
Special Handling
After removing the amount required, tightly close the vial with the
lid immediately after use.
Always bring the vial to +15 to +25°C and mix X-tremeGENE HP
DNA Transfection Reagent prior to removing the amount required
vortexing for one second.
Do not aliquot X-tremeGENE HP DNA Transfection Reagent; store
in the original glass vials.
Minimize the contact of undiluted X-tremeGENE HP DNA Transfection Reagent with plastic surfaces.
For use, the minimum amount of X-tremeGENE HP DNA Transfection Reagent: DNA complex is 100 µl. Complex formation at lower
volumes can significantly decrease transfection efficiency.
Do not use tubes or microplates made of polystyrene for
X-tremeGENE HP Transfection Reagent : DNA complex preparation. When not able to avoid polystyrene materials, make certain to
pipet the transfection reagent directly into the serum-free medium
(e.g., Opti-Mem).
Do not use siliconized pipette tips or tubes.

0114.06479774001!

Additional Equipment and Reagents Required
Additional reagents and equipment required to perform transfection
assays using X-tremeGENE HP DNA Transfection Reagent include:
➤ Standard Laboratory Equipment.
" Standard cell culture equipment (e.g., biohazard hoods, incubators)
" Standard pipettes and micropipettes
" Vortex mixer
➤ For Plasmid Preparation
" Purified plasmid stock (0.1 – 2.0 µg/µl) in sterile TE (10 mM Tris,
1 mM EDTA, pH 8.0) buffer or sterile water
" Genopure Plasmid Midi Kit* or Genopure Plasmid Maxi Kit* to
prepare plasmid
➤ For Verification of Vector Function
" Assay appropriately for transfected gene
" G-418 Solution* or Hygromycin B* (optional for stable transfection experiments)
➤ For Transfection-Complex Formation
" Opti-MEM I Reduced Serum Medium or serum-free medium
" Sterile polypropylene tubes or round-bottom 96-well plates
➤ Growing Cells
" Select subconfluent cultures in log phase for preparation of cell
cultures
" Quantify cell number to reproducibly plate the same number of
cells
Application
X-tremeGENE HP DNA Transfection Reagent is a high performance
transfection reagent, free of animal-derived components. Benefits of
X-tremeGENE HP DNA Transfection Reagent include:
• Designed to transfect a broad range of eukaryotic cells, including
insect cells, many cell lines not transfected well by other reagents,
and hard-to-transfect cell lines (e.g., HT-1080, K-562, HepG2).
• Can be successfully used in a variety of applications, such as gene
expression analysis and protein production using transiently transfected cells, generation of stable cell lines, expression of shRNA for
gene knockdown studies, drug discovery programs, and target
evaluation. Samples and detailed transfection protocols are available at http://www.powerful-transfection.com.
• Produces minimal cytotoxicity or changes in morphology when adequate numbers of cells are transfected, eliminating the requirement
to change media after adding the transfection complex.
• Suitable for transient and stable transfection.
• Functions very well in the presence or absence of serum.
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2.

How to Use this Product

2.3

2.1

Before You Begin

!

Allow X-tremeGENE HP DNA Transfection Reagent, DNA and
diluent to equilibrate to +15 to +25°C. Briefly vortex the
X-tremeGENE HP DNA Transfection Reagent vial.

"

Dilute DNA with appropriate diluent (e.g., serum-free
medium) to a final concentration of 1 µg plasmid DNA /100 µl
medium (0.01 µg/µl). Mix gently.

#

Place 100 µl of diluent, containing 1 µg DNA into each of four
sterile tubes labeled 1:1, 2:1, 3:1, and 4:1.
Use a minimum of 100 µl of diluent. Lower volumes may
significantly decrease transfection efficiency.
Use sterile tubes or tissue culture treated round-bottom,
96-well plates to produce the complex.

$

Pipet the X-tremeGENE HP DNA Transfection Reagent (1, 2, 3,
or 4 µl) directly into the medium containing the diluted DNA
without coming into contact with the walls of the plastic tubes.
Mix gently.
To avoid adversely affecting transfection efficiency, do not
allow undiluted X-tremeGENE HP DNA Transfection
Reagent to come into contact with plastic surfaces. Do not
use siliconized pipette tips or tubes.

%

Incubate the transfection reagent:DNA complex for 15 minutes at +15 to +25°C.
Some ratios and cell types may required longer incubation
(up to 30 min). Determine this for your particular cell line
and the ratio used.

&

Remove the culture vessel from the incubator. Removal of
growth medium is not necessary. Add the transfection complex to the cells in a dropwise manner.
See Table 1 to determine component amounts corresponding to the surface area of the cell culture vessel
used.
Gently shake or swirl the wells or flasks to ensure even distribution over the entire plate surface. If available, use a rotating
platform shaker for 30 seconds at low speed for mixing
96-well plates.
Once the transfection reagent: DNA complex has been added
to the cells, there is no need to replace with fresh medium (as
may be necessary with other transfection reagents)

'

Following transfection, incubate cells for 18 – 72 hours before
measuring protein expression. The duration of incubation will
depend on many factors, including the transfected vector construct, the cell type being transfected, the cell medium, cell
density, and the type of protein being expressed. After the
incubation period, measure protein expression using an assay
appropriate for your system.

Required Amount of X-tremeGENE HP DNA Transfection
Reagent
To optimize, first transfect a monolayer of cells that is 70 - 90% confluent, using 1:1, 2:1, 3:1 and 4:1 ratios of microliter (!l) X-tremeGENE HP
DNA Transfection Reagent to microgram (!g) DNA. A ratio of 3:1 of
microliter (!l) X-tremeGENE HP DNA Transfection Reagent to microgram (!g) DNA has been shown to be optimal for many cell types.
Lower cell confluencies have also been tested successfully.
The recommended starting concentration is a 3:1. For most cell types,
these X-tremeGENE HP DNA Transfection Reagent to DNA ratios provide excellent transfection efficiency.
Further optimization may increase transfection efficiency in your
particular application. In addition to varying the ratio, other parameters may also be evaluated, such as the amount of transfection
complex added. For additional optimization guidelines, see Section
3, Troubleshooting and visit
http://www.powerful-transfection.com.
Plasmid DNA
• For best results, accurately determine the plasmid DNA concentration using 260-nm absorption; estimates of DNA by measuring gel
band density are not recommended. Determine DNA purity using a
260 nm/280 nm ratio (the optimal ratio is 1.8).
• Prepare the plasmid DNA solution using sterile TE (Tris/EDTA) buffer or sterile water at a concentration of 0.1 to 2.0 µg/µl.
• Use high quality DNA preparation kits to obtain endotoxin-free
DNA.
Cell Culture Conditions
• Minimize intra- and inter-experimental variance in transfection efficiency using cells that are regularly passaged, proliferating well in a
log-growth phase, and plated at a consistent density.
• For best results, accurately quantify cell concentration using a
hematocytometer or automated system.
• Cells must be healthy and free of Mycoplasma.
• Cells should have a low passage number to achieve best results.
Other Media Additives
In some cell types, antimicrobial agents (e.g., antibiotics and fungicides) commonly included in cell-culture media may adversely affect
the transfection efficiency of X-tremeGENE HP DNA Transfection
Reagent. If possible, exclude additives in initial experiments. Once
high-efficiency conditions have been established, these components
can be added back while monitoring transfection results. Cell growth
and/or transfection efficiency may be affected by variations in serum
quality and medium formulations.

Transfection Procedure

Notes:
As with any experiment, include appropriate controls. Prepare culture wells with cells that remain untransfected, cells with transfection reagent alone, and cells with DNA alone.
For stable transfection experiments, the complex-containing
medium should be left unchanged until the cells are passaged. At
that time, include appropriate selection antibiotics (e.g., G 418
Solution or Hygromycin B).
To prepare transfection complexes for different-sized containers
or parallel experiments, adjust component amounts corresponding to the surface area of the cell culture vessel used (see
Table 1).
For ease-of-use when transfecting small volumes into 96-well
plates containing 0.1 ml culture medium per well, prepare 100 µl
of transfection complex, and then add 10 µl to each well (depending on cell type).
The optimal ratio of transfection reagent to DNA, and the optimal
total amount of complex, will depend on the cell line, cell density,
day of assay, and gene expressed.
After performing the optimization experiment in which several different ratios are tested, select a ratio in the middle of the plateau
optimum for future experiments.

Verification of Vector Function
Optimize transfection conditions using a known positive-control
reporter gene construct before transfecting cells with a new vector
construct:
• Determine transfection efficiency using a reporter gene assay, such
as "-Gal*, Luciferase*, or SEAP*.
• Sequence flanking vector insert regions to verify the integrity of
your new construct.
2.2
Preparation of Cells for Transfection
Adherent Cells: Plate cells approximately 24 hours before transfection making sure cells are at the optimal concentration in the appropriate cell culture vessel.
Suspension Cells: Plate freshly passaged cells at optimal concentration.

2
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Tab. 1: Guidelines for Preparing X-tremeGENE HP DNA Transfection Reagent: DNA Complex for Various Culture Vessel Sizes

Culture vessel

Surface Area
(cm²)

Total volume of
medium (ml)

Suggested
amount of
100 µl
transfection
complex
to add to
each well (µl)

DNA (µg)
using 1:1
or 4:1 Ratio

Final amount
of X-tremeGENE
HP DNA
Transfection
Reagent (µl)
using 1:1 Ratio

Final amount
of X-tremeGENE
HP DNA
Transfection
Reagent (µl)
using 4:1 Ratio

96-well plate
(1 well)

0.3

0.1

10

0.1

0.1

0.4

48-well plate
(1 well)

1.0

0.3

30

0.3

0.3

1.2

24-well plate
(1 well)

1.9

0.5

50

0.5

0.5

2

12-well plate
(1 well)

3.8

1

100

1

1

4

35-mm dish

8

2

200

2

2

8

6-well plate
(1 well)

9.4

2

200

2

2

8

60-mm dish
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5

500

5

5

20

10-cm dish

55

10

1000

10

10

40

T-25 flask

25

6

600

6

6

24

T-75 flask

75

20

2000

20

20

80

2.4

Troubleshooting

Observation

Possible Cause

Low Transfection
Efficiency

Suboptimal X-tremeGENE HP DNA Transfec- Titrate optimal X-tremeGENE HP DNA Transfection Reagent : DNA
tion Reagent : DNA ratio
ratio. Refer to the text in Section 2.1 “Before you begin”.
Insufficient number of cells

Recommendation

Determine optimal cell density for each cell type. For most cell types, 70
– 90% confluence at transfection is optimal.

X-tremeGENE HP DNA Transfection Reagent : Prepare complexes in serum-free medium (e.g., Opti-MEM).
DNA complexes did not form well
Do not use siliconized pipet tips or tubes.
Do not aliquot the X-tremeGENE HP DNA Transfection Reagent.
Incubation time of transfection

Determine the optimal incubation time (18 - 72 h). Optimal for most cell
types and plasmids is 24 – 48h.

Inhibition by media components

Some media components (e.g., polyanions) may influence the transfection.

Low volume of X-tremeGENE HP DNA Trans- The minimum amount of X-tremeGENE HP DNA Transfection Reagent
fection Reagent : DNA complex
to DNA complex is 100 µl. Complex formation at lower volumes may significantly decrease the transfection efficiency; refer to the text in Section
1, “Special Handling”.
High Cytotoxicity

Cell density not optimal

For each cell type, the optimal density should be determined. For most
cell types, 70 - 90 % confluence at transfection is recommended, but
other confluencies may increase cell viability.

Cells are cultured in serum-free medium

Transfection using X-tremeGENE HP DNA Transfection Reagent in cells
cultured in serum-free medium is possible, however, toxicity may be
higher when serum is absent.

X-tremeGENE HP DNA Transfection Reagent : Add X-tremeGENE HP DNA Transfection Reagent dropwise to the cells.
DNA complexes and cells not mixed well
Gently rock the dish/plate back and forth and from side to side to evenly
distribute the complexes.
Plasmid preparation contaminated with endo- Use highly purified, contaminant-free DNA for transfection.
toxin
Transfected protein is cytotoxic or is produced Reduced viability or slow growth rates may be due to high levels of proat high levels
tein expression, with cellular metabolism directed toward production of
the heterologous protein. Note that the expressed protein may also be
cytotoxic at the expressed levels.
Too much transfection complex for number of Increase the number of plated cells, and/or decrease the total amount of
cells
complex added to the cells.

23
3

www.roche-applied-science.com

Protein Extraction Protocol
1)

Do all steps on ice or at 4o.

2)

Rinse cells with 1X PBS (1 ml, ice cold)

3)

Add 0.5 ml lysis buffer/well

4)

Incubate on ice for 20 min.

5)

Scrape into microfuge tube

6)

Transfer extract to Dounce homogenizer and homogenize with 10 strokes of
Dounce homogenizer (tight pestle)

7)

Transfer extract back to microfuge tube

8)

Spin in microfuge in cold room for 10 min at max speed

9)

Transfer supernatant to new tube. Save pellet.

Igepal-DOC lysis buffer
1% Igepal
0.4% deoxycholate
10mM Tris pH7.
6.6mM EDTA
-add 1X protease inhibitor cocktail before using lysis buffers
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SDS polyacrylamide gel electrophoresis and Western Blot
Materials
BCA protein assay (Pierce Biotech, cat. #23225)
Mini-PROTEAN II gel apparatus (Biorad)
Costar gel-loading tips (Krackler Scientific, cat. #MN520R-LRS)
Prestained SDS-Page broadrange molecular weight standard (NEB, cat. #P7708S)
Trans-blot Semi-Dry Transfer cell (Biorad)
Immobilon-P membrane (Millipore, cat. #IPV00010)
heat-sealable bags (Kapak, cat. #TRS-95250)
Kodak Biomax light autoradiagraphy film, 13 x 18 cm (Perkin Elmer Life Sciences, cat.
#868-9358)
Radtape (Diversified Biotech, cat. #RAD-10)
Reagents
TEMED (Sigma)
Tween-20 (Sigma)
Price Chopper non-fat dry milk
Isopropanol (Sigma)
Gel Buffers
Acrylamide solution (30% acrylamide/0.8% bis-acrylamide)
-dissolve 30g acrylamide (FW=71.08), 0.8g bis-acrylamide (FW=154.17) in a
total volume of 100ml water. Filter through 0.2um filter.
4X Running Gel Buffer (1.5M Tris, pH 8.8)
-dissolve 36.3g Tris Base (FW=121.1) in 150ml water. Adjust to pH 8.8. Add
water to total volume of 200ml. Filter through 0.2um filter.
4X Stacking Gel Buffer (0.5M Tris, pH 6.8)
-dissolve 12.1g Tris Base (FW=121.1) in 150ml water. Adjust to pH 6.8. Add
water to total volume of 200ml. Filter through 0.2um filter.
10% SDS
-dissolve 10g SDS (FW=288.38) in a total volume of 100ml water.
10% Ammonium Persulfate
-dissolve 1.0g APS (FW=228.2) in a total volume of 10ml water. Store at -20˚C in
50-100ul aliquots.
1M Tris, pH 6.8
-dissolve 12.1g Tris Base (FW=121.1) in 80ml water. Adjust to pH 6.8. Add
water to total volume of 100ml. Filter through 0.2um filter.
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6X SDS Sample Buffer (0.375M Tris pH 6.8, 12% SDS, 60% glycerol, 0.6M DTT,
0.06% bromophenol blue)
-combine 3.75ml 1M Tris-Cl, pH 6.8, 6ml glycerol, 1.2g SDS (FW=288.38), 0.93g
DTT (FW=154.2), 6mg bromophenol blue. Add water to total volume of 10ml.
Store at -20˚C in 0.5ml aliquots.
2X SDS Sample Buffer (0.125M Tris pH 6.8, 4% SDS, 20% glycerol, 0.2M DTT,
0.02% bromophenol blue)
-combine 2.5ml 4X Tris pH 6.8 (stacking gel buffer), 2ml glycerol, 4ml 10% SDS
(FW=288.38), 0.31g DTT (FW=154.2), 2mg bromophenol blue. Add water to total
volume of 10ml. Store at -20˚C in 0.5ml aliquots.
1X SDS Sample Buffer (0.0625M Tris pH 6.8, 2% SDS, 10% glycerol, 0.1M DTT,
0.01% bromophenol blue)
5X Electrophoresis Buffer (0.125M Tris, 0.96M glycine, 0.5% SDS)
-dissolve 30.3g Tris Base (FW=121.1), 144.1g glycine (FW=75.07), and 10g SDS
(FW=288.38) in a total volume of 2L water.
1X Electrophoresis Buffer (0.025M Tris, 0.192M glycine, 0.1% SDS)
-add 200ml 5X electrophoresis buffer to 800ml water.
Western Blot Buffers
Transfer Buffer (0.048M Tris, 0.039M glycine, 20% methanol, 0.00375% SDS)
-dissolve 11.64g Tris Base (FW=121.1), 5.86g glycine (FW=75.07) in ~1500ml
water. Add 0.750ml 10% SDS (FW=288.38). Add 400ml methanol. Add water to
total volume of 2L. No pH adjustment necessary.
10X TBST Wash Buffer (0.1M Tris HCl, 1.5M NaCl, 0.5% Tween-20)
-dissolve 31.52g Tris HCl (FW=157.6), 175.32g NaCl (FW=58.44) in ~1900ml
water. Add 10ml
Tween-20. Adjust to pH 7.2. Add water to total volume of
2L.
1X TBST Wash Buffer (0.01M Tris HCl, 0.15M NaCl, 0.05% Tween-20)
-add 100ml 10X TBST to 900ml water.
5% milk Blocking Buffer
-Dissolve 5g milk in a total volume of 100ml 1X TBST.
Method
1. Determine cell number or protein concentration to be loaded onto gels and what
volume to load per well. Note max volumes for different comb configurations.
2. Usually add sample to Tris or PBS and then add sample buffer (2 ul sample + 18 ul
PBS + 3.3 ul 6X sample buffer).
3. Sonicate cells briefly on ice to homogenize. Purified protein samples do not need to be
sonicated.
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4. Preparing resolving and stacking gels (for BioRad Mini-PROTEAN II): Make sure
glass plates are clean. Use Sparkleen or Alconox powder to clean plates. Rinse with
distilled water and then 95% EtOH. Wipe dry with KimWipes. Select a comb and spacer
(ex. 0.75 mm). Place spacers in between the inner and outer glass plates. Make sure that
the spacers are flush with the plates. Insert plates into the clamping assembly and tighten
screws. Vacuum grease can be used on the casting stand gaskets to prevent buffer
leakage. Snap assembly into the casting stand. Prepare resolving gel. Pour gel and
overlay with 1X Electrophoresis Buffer or isopropanol (use 3.5ml resolving gel when
using 0.75mm spacers and 7.0ml gel for 1.5mm spacers, this will produce a gel approx.
3.25" x 2"). Look for a division between the overlay and resolving gel, this means the gel
is polymerized. Pour off overlay, use thin strips of Whatman paper to remove any
excess. Pour stacking gel and insert comb. Remove comb when stacking gel is
polymerized. Use a syringe and a 12 gauge needle to wash stacking gel wells. Snap
clamp assembly into electrode assembly. Vacuum grease can be used on electrode
assembly gaskets to prevent buffer leakage.
5. Boil samples 5 minutes at 100°C, and then spin tubes at 13,000rpm for ~1min. in RT
micro centrifuge. Load samples using Costar Gel-Loading Tips.
6. Place electrode assembly with loaded samples into an electrophoresis chamber. Fill the
electrode assembly carefully with 1X Electrophoresis Buffer. Fill the electrophoresis
chamber with 1X Electrophoresis Buffer. Run gels at 100V for stacking gel, 100-150V
for resolving gel (can increase to 200V for resolving gel if running on ice).
7. To transfer mini- gels to Immobilon-P membrane using the BioRad Semi-Dry Transfer
Cell: Remove gels from glass plates. Cut stacking gel away and discard. Incubate gels in
Transfer Buffer for 20 - 40 min. Cut out 6 pieces of Whatman paper and 1 piece of
Immobilon-P membrane for each gel that is being transferred. They should be 3.25" x 2".
Incubate Immobilon-P membrane in Methanol for ~10 - 20 seconds. Wet Immobilon-P
membrane and Whatman paper in Transfer Buffer for 5 - 10 minutes before assembling
the gel sandwich according to the BioRad Reference Guide. Transfer 1 mini-gel for 15
min. at 15 V, max current. Transfer 2 mini-gels for 30 min at 15 V, max current. Make
sure that pre-stained MW markers transfer to Immobilon-P membrane.
8. Western Blot:
-Block membrane in 20ml blocking buffer overnight at 4°C or 1h at room
temperature on rocker in a seal-a-meal bag.
-Dilute Ab in blocking buffer (1:1000 for serum or 5ug / 10ml for purified Ab).
Incubate blots with Ab for 1h at rom temperature or overnight at 4°C on rocker in
a seal-a-meal bag.
-Wash blots with 50ml 1X TBST on orbital shaker 3 times, 5 minutes each.
-Dilute HRP conjugated Ab 1:10,000. Incubate blots with secondary Ab for 1h at
room temperature or overnight at 4°C on rocker in a seal-a-meal bag.
-Wash blots with 50ml 1X TBST on orbital shaker 3 times, 5 minutes each.
-Add 5ml chemiluminescent substrate to each blot, incubate for 5 minutes. Place
blots in between transparency film. Push out air bubbles. Develop Western blot.
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Do a 1 minute exposure to check signal intensity. Continue with longer or shorter
exposures as needed.
(Max. exposure length = 60 min. Min exposure length = 1 sec.)
-For high backgrounds, wash in TBST then re-develop.
Resolving Gel
7.5% gel (15ml)

10% gel
(15ml)

15% gel
(15ml)

7.5ml

6.25ml

3.75ml

3.75ml

5ml

7.5ml

3.75ml

3.75ml

3.75ml

10% SDS

150ul

150ul

150ul

10% APS

50ul

100ul

50ul

TEMED

10ul

20ul

10ul

Water
30%
acrylamide/
0.8% bisacrylamide
4X Running
Buffer

Running Gel: 7.5, 10, or 15% acrylamide, 0.375M Tris-Cl pH 8.8, 0.1% SDS, 0.33%
APS, 0.66% TEMED
Stacking Gel
4% gel (10ml)
Water

6.1ml

30% acrylamide/
0.8% bis-acrylamide

1.3ml

4X Stacking Buffer

2.5ml

10% SDS

100ul

10% APS

100ul

TEMED

40ul

Stacking Gel: 4% acrylamide, 0.125M Tris-Cl pH 6.8, 0.1% SDS, 0.05%APS, 0.2%
TEMED
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Protocol for non-permeabilizing IHC.
1. Wash cells with 0.5ml 1X PBS
2. Fix cells for 10 minutes at RT with 0.5ml 4% paraformaldehyde in 1X PBS
3. Aspirate PFA and add 0.5ml 10mg/ml Glycine in 1X PBS for 10 minutes
4. Block cells for 20 minutes with 0.5ml 5% BSA in 1X PBS
5. Wash with 0.5ml 1X PBS.
6. Incubate with primary antibody for 60 minutes. Antibody concentration is 1.0
µg/ml in 0.5ml PBS with 5% BSA.
7. Wash with three 0.5ml changes of PBS for 5 minutes each.
8. Incubate for 45 minutes with secondary antibody diluted to 1µg/ml in 0.5ml PBS
with 5% BSA.
9. Wash with three 0.5ml changes of PBS.
10. Mount coverslip with Vectashield or 90% glycerol in PBS with n-propyl galate
(about 10ml).
11. Store slides in a dark location at 4° C
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